// App-Quantinova.ai

e23210 : IDH-1/2 mutations and associated oncometabolite 2-hydroxyglutarate (2-HG) in solid tumors.

Researchers

Presenter

  • Nazanin Fallah-Rad

Principal Investigators

  • Philippe L. Bedard

  • Lillian L. Siu

  • Stefano Serra

  • Suzanne Kamel-Reid

  • Marcus O. Butler

  • Anthony M. Joshua

  • Celeste Yu

  • Helen Chow

  • Zhang Weijiang

  • Jennifer J. Knox

  • Monika K. Krzyzanowska

  • Geoffrey Liu

  • Raymond Woo-Jun Jang

  • Albiruni Ryan Abdul Razak

  • Eric Xueyu Chen

Medical Centers

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Princess Margaret Cancer Centre, University Health Network, Division of Medical Oncology and Hematology, Toronto, ON, Canada

  • Department of Pathology and Laboratory Medicine, University Health Network, Toronto, ON, Canada

  • Ontario Cancer Institute, Princess Margaret Hospital, Toronto, ON, Canada

  • Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, ON, Canada

  • Princess Margaret Cancer Centre University Health Network, Toronto, Ontario, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved